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Human metapneumovirus (HMPV) is a member of the
subfamily  Pneumovirinae within the family Paramyxo-
viridae. Other members of this subfamily, respiratory syncy-
tial virus and avian pneumovirus, can be divided into sub-
groups on the basis of genetic or antigenic differences or
both. For HMPV, the existence of different genetic lineages
has been described on the basis of variation in a limited set
of available sequences. We address the antigenic relation-
ship between genetic lineages in virus neutralization
assays. In addition, we analyzed the genetic diversity of
HMPV by phylogenetic analysis of sequences obtained for
part of the fusion protein (n = 84) and the complete attach-
ment protein open reading frames (n = 35). On the basis of
sequence diversity between attachment protein genes and
the differences in virus neutralization titers, two HMPV
serotypes were defined. Each serotype could be divided
into two genetic lineages, but these did not reflect major
antigenic differences.
H
uman metapneumovirus (HMPV) has recently been
identified as a causative agent of respiratory tract ill-
nesses in humans worldwide (1–3) and is a member of the
Pneumovirinae subfamily within the Paramyxoviridae
family (4). The Pneumovirinae subfamily consists of two
genera: the pneumoviruses and the metapneumoviruses.
Human respiratory syncytial virus (HRSV), the major viral
cause of severe respiratory tract illnesses in children, is the
type species of the pneumoviruses (5). Avian pneumovirus
(APV), the causative agent of respiratory tract illnesses in
turkeys and chickens (6), was the sole member of the
Metapneumovirus genus until the discovery of HMPV (7).
For most pneumoviruses, different subgroups or sub-
types have been identified. For HRSV, two subgroups have
been identified on the basis of differences in nucleotide
sequences, reactivity patterns with monoclonal antibodies,
and in vitro neutralization assays with subgroup-specific
antisera (8–11). Additional genotypes have been identified
within subgroups, largely on the basis of the high variabil-
ity of the attachment protein gene (12,13). The fusion (F)
and the attachment (G) proteins are the main targets for the
neutralizing and protective antibody response (14–16),
with F being one of the most conserved proteins and G the
most variable (17–20). For APV, two different subgroups
(A and B) have been defined on the basis of nucleotide
sequences of the G protein and neutralization tests by
using monoclonal antibodies that also recognize the G pro-
tein, but these subgroups belonged to one serotype (21).
APV type C, a possible second serotype, was identified
based on the lack of cross-reactivity with antisera specific
for groups A and B, and the nucleotide sequences also
proved to be substantially different from strains belonging
to group Aor B (22,23). In addition, subgroup D may exist,
which contains isolates from France that are not neutral-
ized by monoclonal antibodies raised against viruses
belonging to either subgroup A, B, or C (24).
For HMPV, two major genetic lineages have been iden-
tified worldwide on the basis of analysis of a limited set of
sequences (25–27). One feature of HMPV that poses a
challenge in developing a future vaccine is that infections
may occur in the presence of preexisting immunity. Very
young children (<1 year) have been infected by the virus,
and reinfections have also been demonstrated (28). HMPV
might cause repeated infections throughout life, similar to
HRSV, which could be either due to incomplete immunity
or to genetic heterogeneity of the virus. 
To develop vaccines, the extent of genetic and anti-
genic variability of the different HMPV transmembrane
glycoproteins must be understood. We analyzed the genet-
ic diversity of HMPV by phylogenetic analyses of
sequences obtained for part of the F (n = 84) and the com-
plete G open reading frames (ORFs) (n = 35). In addition,
we addressed the antigenic relationship between the dif-
ferent lineages with virus neutralization assays using lin-
eage-specific antisera raised in ferrets. Virologic studies
have used a definition of a homologous-to-heterologous
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serotypes (29). On the basis of our results and the
described definition, we now define the two major lineag-
es of HMPV as serotype A and B. In accordance with the
definition and our results, the sublineages within each
serotype are not identified as different serotypes. At least
two serotypes of HMPV are present in the human popula-
tion, a finding that has implications for developing inter-
vention strategies, such as immunization and vaccination.
Materials and Methods
Sample Collection, RNA Isolation, 
RT-PCR Assays, and Sequencing
HMPV-positive nasopharyngeal aspirate samples were
obtained from different cohort studies: 61 samples from
the Netherlands, 11 samples from Finland, 8 samples from
England, 1 from Hong Kong, and 2 from Brazil. Clinical
samples had been obtained from 1981 to 2002. Samples
were obtained from young children, infants, adults, the
elderly, and immunocompromised persons, who had mild
to severe respiratory tract illnesses. Epidemiologic and
clinical data for most isolates have been described else-
where (30–32).
Similar to the influenza nomenclature, sequences are
identified by country of origin, identification number, and
year of isolation. RNA isolation was performed as
described previously (25). cDNAwas synthesized at 42°C
for 60 min with random hexamer primers (Promega,
Leiden, the Netherlands) and superscript II RNase H-
reverse transcriptase (RT) (Invitrogen, Merelbeke,
Belgium). An aliquot of cDNA was used in a polymerase
chain reaction (PCR) assay to amplify the full-length G
ORF or a fragment of the F ORF. Primers: SH7: 5′-




AAAC-3′ (F ORF). Thermocycling was performed under
the following conditions: 94°C for 1 min, 40°C for 2 min,
72°C for 3 min (40 cycles). When necessary, a nested
PCR was performed by using 5 µL of PCR product with
primers SH7 and SH8 for the G ORF or primers BF103 5′-
ACATGCCAACATCTGCAGGACAAATAAAAC-3′ and
BF104 5′-ACATGCTGTTCACCTTCAACTTTGC-3′ for
the F ORF. PCR products were sequenced directly on both
strands with multiple primers as described previously
(25). When identical sequences were obtained (suspicious
of laboratory contamination) and to confirm sequence
uncertainties such as frame shifts, we repeated the RNA
isolation, RT-PCR, and subsequent sequencing with the
original materials.
Phylogenetic Analysis 
Nucleotide sequences were aligned with the Clustal W
program running within the Bioedit software package, ver-
sion 5.0.9. Maximum likelihood trees were generated with
the Seqboot and Dnaml packages of Phylip version 3.6 by
using 100 bootstraps and 3 jumbles. The consensus tree
was calculated by using the Consense package of Phylip
3.6 and was subsequently used as usertree in Dnaml to
recalculate the branch lengths from the nucleotide
sequences. Finally, the trees were rerooted at midpoint by
using the Retree software of Phylip 3.6. Trees were visual-
ized with the Treeview 1.6.6 program distributed with
Bioedit version 5.0.9 (33). Sequences are available from
GenBank under accession no. AY295930 to AY296012 (F
partial) and AY304360 to AY304362 (complete F for
NL/17/00, NL/1/99, and NL/1/94, respectively),
AF371337 (complete genome NL/1/00), and AY296014 to
AY296047 (complete G regions).
Virus Preparations and Titrations
Viruses were isolated on tertiary monkey kidney (tMK)
cells as previously described (25). For each genetic lineage
a prototype virus isolate was chosen on the basis of its abil-
ity to grow to high titers on tMK cells and to reflect the
specific genotype for the lineage. Virus titrations were cul-
tured for 7 days, and infected wells were identified by
immune fluorescence assays (IFA) with HMPV-specific
polyclonal antiserum raised in guinea pigs. Titers were
expressed in 50% tissue culture infectious dose (TCID50).
Antisera 
Lineage-specific polyclonal HMPV antisera were raised
by infecting ferrets with 1 mL of virus-infected tMK super-
natants containing approximately 104–105TCID50 virus. All
infections were performed in duplo, and the animals with
the highest antibody responses are shown. Serum samples
were collected at days 0 and 28 postinfection (ferret 1 and
2) or at days 0 and 21 (ferret 3 to 6). Infections were per-
formed as follows: ferrets 1 and 3: HMPV NL/1/00, proto-
type virus for lineage A1. Ferrets 2 and 5: HMPV NL/1/99,
prototype virus for lineage B1. Ferret 4: HMPV NL/17/00,
prototype virus for lineage A2 and ferret 6: HMPV
UK/5/01 a virus from lineage B2. Ferrets were housed in
isolator cages to avoid cross-infections.
HMPV-specific polyclonal antisera were raised in
guinea pigs as previously described (25). Antisera raised in
separate guinea pigs against viruses from the two main
genetic lineages (A and B) were mixed 1:1, and this mix-
ture tested positive against all HMPV isolates in IFA.
Virus Neutralization Assays
Virus neutralization assays of heat-inactivated (30 min
56°C) ferret serum samples were performed as previously
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starting at 1:8 were incubated with approximately 30
TCID50 virus. Seven days after infection of tMK cells with
the antibody and virus mixture, IFA was performed with
the guinea pig antiserum. The virus neutralization titer was
defined as the reciprocal of the highest serum dilution at
which no positive IFA signal was obtained (depicted as
means of duplicate measurements). Each experiment
included virus titrations of the working solution of the
virus, using twofold dilutions, and 10–100 TCID50 per well
was considered acceptable.
Results
Variation in the Fusion Protein Gene
Partial F gene sequences (nucleotide [nt] 780–1,221 in
the F ORF) were obtained from clinical samples collected
from 84 HMPV-infected patients. Phylogenetic analysis of
these sequences confirmed two main genetic lineages, A
and B. Each of these lineages appeared to consist of two
sublineages, which were tentatively named A1, A2, B1,
and B2 (Figure 1A).
Comparison of the sequences showed high percentage
identities between members of the same sublineage (nt:
97%–100%, amino acids [aa]: 99%–100%), members of
the two different sublineages within each main lineage (nt:
94%–96%, aa: 97%–99%), and between members of the
two different main lineages A and B (nt: 84%–86%, aa:
94%–97%). Whereas no specific amino acid residue sub-
stitutions could be found between sequences from sub-
groups A1 and A2, there were 5 specific aa substitutions
between sequences from genotypes A and B, and one sub-
stitution between B1 and B2 (Table 1). The low variability
was also observed when complete F protein genes from
prototype viruses for each sublineage were sequenced
(Figure 2).
Variation in the Attachment Protein Gene
Nucleotide sequences of the region between the start
codons of the G and the polymerase (L) reading frame
were obtained for 35 samples. Phylogenetic analysis
showed the same clustering of the sequences over the four
sublineages as seen for the F protein gene (Figure 1B). The
G region showed some variation in length, from 860 nt to
908 nt. The first 657–708 nt have been described as the
putative primary G ORF (4). Alignment of the primary G
ORFs showed a variation in length, even for members of
the same sublineage, due to single nucleotide substitutions
that resulted in premature termination codons (Figure 3).
For two samples a change in ORF was observed as a result
of an addition (BR/2/01: G at position 519) or a deletion
(NL/2/93: C at position 243) of a single nucleotide. These
mutations resulted in relatively short G ORFs (NL/2/93:
110 aa; BR/2/01: 193 aa) because of premature termination
and in drastic changes in the deduced amino acid
sequences of the carboxy-terminus of the G proteins.
Comparison of the primary G ORF sequences, excluding
sequences of NL/2/93 and BR/2/01 because of the putative
frame shifts, showed a relatively high percentage identity
between members of the same sublineage (nt: 93%–100%,
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Figure 1. Phylogenetic trees constructed based on the (A) partial
F gene (Open reading frame [ORF] position 780–1,221, n = 84) or
(B) the complete G coding region (start G ORF to start L ORF, n =
35). Trees were generated by maximum likelihood analysis using
100 bootstraps and 3 jumbles. The scale representing the percent-
age of nucleotide changes is shown for each tree. Bootstrap val-
ues are based on the consensus trees, and relevant numbers are
shown in the tree. The four prototype viruses are shown in bold-
face, with ovals drawn around them. NL, viruses from the
Netherlands; FN, viruses obtained from Finland; UK, viruses
obtained from the United Kingdom; HK, viruses obtained from
Hong Kong; BR, viruses obtained from Brazil.aa: 75%–99.5%), less identity between members of the
two different sublineages within each main lineage (nt:
76%–83%, aa: 60%–75%), and low sequence identity
between members of the two different main lineages Aand
B (nt: 50%–57%, aa: 30%–37%). 
The position of the hydrophobic domain, a high per-
centage of proline, serine, and threonine residues and a
cysteine residue at position 27 are features shared by all
HMPVs. Whereas the cytoplasmic tail was conserved
among all members (58%–70% aa identity), the proposed
ectodomains (start aa 51) were quite variable (18%–25%
aa identity between lineage A and B). The number and
position of potential sites for N-linked glycosylation sites
varied even within each sublineage, from two to six poten-
tial sites, with one located at the proposed cytoplasmic tail
conserved among all lineages.
Geographic and Temporal Distribution
Analysis of HMPV sequences obtained from samples
received from different countries indicated that sequences
from Finland, the United Kingdom, and the limited
sequences from Asia and South America, were found on
branches between the Dutch sequences in the F tree, and
not as a separate lineage. The variation between sequences
obtained from samples from a single country was found in
the same range as the variation found between samples
obtained from different countries. In agreement with the
genetic lineages of HMPV observed worldwide, which
usually includes sequences similar to those of isolate
NL/1/00 or NL/1/99, geographic clustering does not
appear to apply to HMPV.
The different HMPV samples were obtained during the
last 20 years with most from 2000 to 2002 and 14 in the
1990s. As indicator for possible fixation of amino acid
variation over time, we analyzed the G ORF amino acid
sequence of members in sublineage A2 and B1 (containing
samples from 1981 to 2002) in more detail. The amino acid
sequence variation between the viruses from 1981 and
2001 was in the same range as the variation found between
viruses from 2001, and alignments of the sequences did
not indicate fixation of amino acid changes between 1981
and 2002. Thus, antigenic drift, as observed for influenza
A and B viruses, does not appear to be an important phe-
nomenon for HMPV.
Antigenic Variation
To address the antigenic variation between the genetic
lineages A and B, we raised antisera in ferrets against iso-
late NL/1/00, the prototype virus for lineage A1, and
against isolate NL/1/99, the prototype virus for lineage B1.
The serum samples were collected 28 days postinfection
and tested in virus neutralization assays against the homol-
ogous and heterologous viruses. In three independent
experiments, the virus titer used per well varied from 10 to
50 TCID50; this variation did not affect the measured virus
neutralization titers (Table 2). Ferret 1, infected with the
lineage A prototype virus (NL/1/00), showed a 48- to 128-
fold higher virus neutralization titer against the homolo-
gous virus NL/1/00 than to the heterologous virus
NL/1/99. Similarly, ferret 2, infected with the lineage B
prototype virus NL/1/99, had a 16- to 96-fold higher
homologous than heterologous virus neutralization titer.
In a second experiment, ferret antisera were raised to
viruses from all four sublineages. To measure the most
specific serologic response, serum samples were collected
21 days postinfection, after which homologous and
heterologous virus neutralization titers were measured
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Table 1. Lineage-specific amino acid substitutions between the 
four sublineages in the fusion open reading frame between 
position 260 and 407 
Sublineage  aa286  aa296  aa312  aa348  aa404 
A1  V  K  Q  K  N 
A2  V  K  Q  K  N 
B1  I  N  K  R  P 
B2  I  D  K  R  P 
Figure 2. Amino acid sequence comparison of the fusion protein
genes of prototype human metapneumovirus isolates of each sub-
lineage. The predicted signal peptide, fusion domain, and mem-
brane anchor are shown in italics in boldface type, the cleavage
sites are boxed, and the region sequenced for 84 samples is
underlined in boldface type. Periods indicate the position of identi-
cal amino acid residues relative to isolate NL/1/00. (Table 3). Within each main genetic lineage, a high degree
of cross-neutralization was observed between viruses from
the two sublineages (e.g., A1 vs. A2 and B1 vs. B2), which
is reflected in the low ratio between homologous to het-
erologous virus neutralization titer (0.5 to 3.0). Although
serum samples from ferrets 3 to 6 had slightly lower
homologous virus neutralization titers than those of ferrets
1 and 2, serum samples raised against viruses from the
main lineage A still showed a 12- to 24-fold higher virus
neutralization titer against the lineage Aviruses than to lin-
eage B viruses. Similarly, serum samples raised against
viruses from lineage B had a 16- to 43-fold higher virus
neutralization titer against the lineage B viruses than to lin-
eage A viruses. 
Discussion
In this study, the genetic heterogeneity of HMPV was
addressed by analysis of the nucleotide and predicted
amino acid sequences of part of the F (n = 84), complete F
(n = 4), and the complete G (n = 35) protein genes.
Phylogenetic analysis of these sequences showed two
main lineages (Aand B) with each divided into two sublin-
eages (1 and 2). As was described for HRSV and APV, the
F protein was highly conserved, which is in agreement
with F proteins of pneumoviruses having structural and
functional constraints for amino acid mutations (34). On
the basis of the high percentage sequence identity for the
complete F proteins of the prototype viruses of the four lin-
eages, sequences for the complete F proteins of all 84 sam-
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Figure 3. Amino acid sequence comparison of the putative attachment (G) protein of human metapneumovirus strains per genetic sub-
lineage; A1 (A), A2 (B), B1 (C), and B2 (D). For each sublineage only representative samples are depicted, resulting in 24 sequences.
Representative sequences were chosen, so that from each year in which samples were obtained at least one sequence is depicted, and
sequences with only a few amino acid substitutions were omitted. Potential N-linked glysosylation sites are underlined, and periods indi-
cate the position of identical amino acid residues relative to the first sequence in each subgroup. Numbers indicate the nucleotide posi-
tion in the primary G Open reading frames.ples would probably demonstrate similar low variability.
In contrast to the F protein, the nucleotide and predicted
amino acid sequences of the complete G coding regions
showed high sequence diversity (as low as 30%–37% aa
identity). Besides the high amino acid sequence variation,
we observed variation in length of the different G proteins.
Where most of the length variation was due to nucleotide
substitutions, two of the samples showed a change in read-
ing frame due to deletion or addition of single nucleotides.
Frame shift mutations and use of alternative reading
frames have been described for HRSV (35–37). As
described for isolate NL/1/00, the G coding region of the
35 samples sequenced in the present work indicated long
alternative ORFs. However, these secondary ORFs varied
in length and position compared to the ones described (4).
Whether premature stop codons, the incidence of frame
shift mutations, and possible use of alternative reading
frames influence the antigenic properties of the viruses
needs to be examined in more detail.
Phylogenetic analyses showed that the HMPV samples
obtained from different years and from different countries
were randomly distributed over all four sublineages. For
HRSV it has also been reported that very similar viruses
were isolated at different times and from geographically
distant sites (36). Different lineages within HRSV sub-
group A and B have been found on the basis of the varia-
tion in the G protein. Within each subgroup, progressive
accumulation of amino acid changes was noted, suggesting
that the G protein of HRSV might be susceptible to
immune pressure (36). Analysis of the amino acid
sequences of the HMPV samples described in this study
did not indicate such accumulation over time. However the
following observations indicate that the variation of the
HMPV G protein might occur as a result of immunogenic
pressure in a same manner as was postulated for the RSV
G protein: 1) most of the amino acid sequence variation
was found in the extracellular domain of the G protein, 2)
the variation found at the amino acid sequence level was
higher than that at the nucleotide sequence level, 3) the
number and position of potential glycosylation sites were
not conserved, and 4) deletions, additions and substitutions
of single nucleotides resulted in premature stop codons and
drastic changes of the carboxy terminal of the protein
(18,36). Until a larger number of more chronologically
diverse HMPV samples have been examined, this issue
remains inconclusive.
To address the antigenic relationship between members
of the different HMPV lineages, we tested ferret sera
raised against viruses from the four sublineages in virus
neutralization assays. Serologic responses upon infections
tend to broaden over time. On the basis of the relatively
close genetic relationship between sublineages A1 and A2
or B1 and B2, we decided to collect serum samples at an
early time point, to obtain large antigenic differences
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Table 2. Homologous and heterologous virus neutralizing antibody titers of serum samples obtained from ferrets infected with HMPV 
viruses belonging to different genetic sublineages
a,b 
Experiment  Virus used in virus neutralization  TCID50/well  Ferret 1 NL/1/00 [A1]  Ferret 2 NL/1/99 [B1] 
NL/1/00  12  1,024  32  1 
NL/1/99  9  16  512 
NL/1/00  30  1,024  8  2 
NL/1/99  20  8  768 
NL/1/00  40  768  24  3 
NL/1/99  25  16  768 
Ratio A–B      48–128   
Ratio B–A        16–96 
aVirus neutralizing antibody titers obtained in three independent experiments for serum samples collected 28 days postinfection from ferrets 1 and ferret 2 (infected with 
NL/1/00 and NL/1/99 respectively). TCID50, 50% tissue culture infectious dose; HMPV, human metapneumovirus. 
bHomologous virus neutralization titers are bold. Values are average of duplicate measurements. Ratios are given as the homologous virus neutralization titers divided by 
the heterologous virus neutralization titers. 
Table 3. Homologous and heterologous virus neutralizing antibody titers of sera obtained from ferrets infected with HMPV viruses 
belonging to different genetic sublineages
a,b 
Virus used in virus neutralization  Ferret 3 NL/1/00 [A1]  Ferret 4 NL/17/00 [A2]  Ferret 5 NL/1/99 [B1]  Ferret 6 UK/5/01  [B2] 
NL/ 1/00   256  256  6  32 
NL/17/00   512  768  12  24 
NL/ 1/99   16  32  256  384 
UK/ 5/01   12  64  256  512 
Ratio A–B 
Ratio B–A 




aVirus neutralizing antibody titers obtained for sera collected 21 days post infection from ferrets 3 to 6 (infected with NL/1/00, NL/17/00, NL/1/99 and UK/5/01, 
respectively). HMPV, human metapneumovirus. 
bHomologous virus neutralization titers are bold. Values are average of duplicate measurements. Ratios are given as the homologous virus neutralization titers divided by 
the heterologous virus neutralization titers. between the four sublineages. The low homologous virus
neutralization titers in serum samples collected 21 days
postinfection may explain the lower ratio between homol-
ogous and heterologous virus neutralization titers as com-
pared to sera collected 28 days postinfection. The studies
with serum samples collected at 21 days postinfection
showed that viruses within one main lineage (e.g., A1 and
A2 or B1 and B2) were antigenically closely related. The
difference in homologous and heterologous virus neutral-
ization titers between members of the two different lineag-
es A and B titers (12- to 128-fold higher homologous titer
than heterologous titer) indicate a difference in antigenici-
ty between lineage A and B. Classic virology studies have
used a definition of a homologous-to-heterologous virus
neutralization titer ratio of >16 for defining serotypes. This
same definition notes that if neutralization shows a certain
degree of cross-reaction between two viruses in either or
both directions (homologous-to-heterologous titer ratio of
8 or 16), distinctiveness of serotype is assumed if substan-
tial differences in sequences are observed (29). On the
basis of our results, and based on the described definition,
we propose defining the two main lineages of HMPV as
serotypes A and B. The HMPV samples were obtained
from different study populations, from different countries,
and from patients with a wide spectrum of clinical signs.
So far, we have no indication of an association between
infection with either of the serotypes and a specific study
group or with severity of disease. More epidemiologic
studies are needed to address this issue. 
The circulation of two serotypes of HMPV might have
implications for the development of vaccines. Studies in
cynomolgous macaques showed that reinfection is sup-
pressed by high titers of virus neutralization antibodies
against the homologous virus and far less by heterologous
virus neutralization antibodies (data not shown). So far,
one heterologous reinfection has been reported in humans
(28). However, children approximately >5 years of age
have higher virus neutralization antibody titers than those
1–2 years of age (25), which suggests that reinfections
may occur frequently, most likely with the viruses from the
heterologous serotype. For RSV, the importance of differ-
ence in antigenicity between the two subgroups regarding
protective immunity and vaccine development is still a
subject of discussion. However, in animals and humans,
the neutralizing capacity against homologous viruses is
higher than that against heterologous viruses, and in ani-
mals high homologous virus neutralization titers protect
against reinfection. In humans, reinfection often occurs
with a strain from the heterologous group, and high homol-
ogous virus neutralization antibody titers protect against
severe infection (13). The two serotypes of HMPV might
resemble the two subgroups of HRSV in immunogenic
properties, although more extensive epidemiologic and
immunologic studies have to prove this. The cross-reactive
immunity provided by the F protein may be sufficient to
overcome the effects of changes in the G protein. For
HRSV the immune response against the F protein is cross-
reactive between subgroup A and B, whereas the response
against the G protein is subgroup (and sometimes even
genotype) specific (14,16,38). The prophylactic use of a
virus neutralization monoclonal antibody preparation
directed against the HRSV-F protein has been shown to
decrease the severity of lower respiratory tract diseases
caused by both subgroups of RSV (39–41). In a similar
way, the conserved F protein of HMPV could be a target
for the development of monoclonal antibodies for treat-
ment of HMPV-infected persons.
Our data support a technical description of two
serotypes of HMPV in experimentally infected ferrets. The
existence and relevance of these serotypes in other animal
species, including humans, has yet to be determined.
Our results in combination with data published by oth-
ers (26,27,42) demonstrate that HMPV clusters in two
globally distributed serotypes. However, the identification
of two serotypes does not exclude the possible existence of
more serotypes or sublineages. The described viruses were
all identified by using primers against conserved regions in
the genome of the four prototype viruses, but in order to
allow identification of more diverse HMPV strains, virus
isolation of original materials is a standard procedure in
our laboratory.
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